Skip to main content
Premium Trial:

Request an Annual Quote

Microbial DNA Specialist OpGen Pockets $23.6M in Series A VC Cash

NEW YORK (GenomeWeb News) — OpGen has received $23.6 million in Series A private-equity financing that it plans to use to “develop commercial instrumentation systems for the clinical microbiology marketplace.”   
 
OpGen, a Madison, Wisc.-based company specializing in analyzing microbial DNA, also said it is looking for a new chief executive.
 
The cash came from three new venture capital investors, including CHL Medical Partners, Highland Capital Partners, and Versant Ventures. Existing investor Mason Wells also contributed in the round.
 
OpGen said it has added to its board of directors one investor each from Highland and Versant. Ron Lennox from CHL will become chairman of OpGen’s board, the company said. Lennox will be joined on the board by Corey Mulloy and Bijan Salehizadeh from Highland, and Versant's Brian Atwood.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.